What the FDA's 503B removal proposal means for compounded GLP-1 patients

US compounding law distinguishes between two types of compounding pharmacies:

503A pharmacies are traditional compounding pharmacies that make medications for individual patients based on a specific prescription. They compound smaller volumes and serve individual patients.

503B outsourcing facilities are larger operations that can compound drugs in bulk — without a patient-specific prescription — and distribute to hospitals, clinics, and healthcare providers across state lines. They operate more like small manufacturers and are subject to more rigorous FDA oversight.

The 503B Bulks List is the mechanism that allows outsourcing facilities to use certain bulk drug substances to compound drugs. For a drug to be legally compounded by a 503B facility under this pathway, the substance generally needs to be on the 503B Bulks List or on the FDA's active drug shortage list.

Semaglutide and tirzepatide entered the shortage list during supply crunches. When the shortage was declared, compounding was explicitly permitted. When FDA determined the shortage had resolved, it revoked that permission. Now, FDA is proposing to confirm that these drugs don't belong on the 503B Bulks List either — closing the large-scale compounding pathway for these three drugs.

The FDA's rationale, as stated in the Federal Register notice (2026-08552, published May 1, 2026), is that it has determined there is no clinical need to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List — because FDA-approved versions of these drugs are now commercially available and not in shortage.

The clinical need standard is how FDA decides whether a drug substance belongs on the 503B list in the first place. If an approved drug is commercially available and not in shortage, the threshold for clinical need is generally not met.

If the proposal becomes a final rule:

• Large 503B outsourcing facilities would no longer be able to legally compound semaglutide, tirzepatide, or liraglutide in bulk under the 503B exemption.
• Many of the large-volume, lower-cost compounded GLP-1 prescriptions that went through outsourcing facilities would lose their legal compounding pathway under 503B.

What it would not mean:

• It would not automatically prohibit 503A pharmacies from compounding for individual patients with a valid prescription — though 503A compounding has its own requirements and limits.
• It does not affect FDA-approved brand-name medications.

For a concrete example of how FDA enforcement against compounded tirzepatide is already playing out, see our coverage of the ProRx warning letter.

After 503B removal, 503A pharmacies may still compound semaglutide or tirzepatide for specific patients with a valid prescription if the commercially available product doesn't meet the patient's specific needs (e.g., specific dosage form, documented allergy to an inactive ingredient), the pharmacy complies with all 503A requirements, and a clinician documents the clinical rationale.

The practical reality: 503A pharmacies operate at smaller scale, typically serve local patients, and face more clinical justification requirements than outsourcing facilities. Access to compounded GLP-1s through this pathway, if the 503B rule finalizes, would be narrower and more variable by location and prescriber.

• The final rule outcome — the public comment period gives stakeholders an opportunity to influence the decision.
• Whether FDA will issue additional guidance on 503A compounding separately.
• How this interacts with insurance coverage decisions and whether brand-name coverage expands to fill access gaps.
• Timing — even if finalized, rules typically include compliance deadlines before they take effect.

• Is my compounded medication currently supplied through a 503B outsourcing facility or a 503A pharmacy?
• If 503B removal is finalized, what alternatives exist for my situation?
• Is my insurance coverage likely to change if compounded options narrow?
• Are there any patient assistance programs for brand-name semaglutide or tirzepatide I should know about?

The FDA's 503B removal proposal is a significant development for people who access compounded GLP-1 medications. It is not a ban on all compounding — but if finalized, it would close the largest compounding channel and narrow access meaningfully.

The comment period is still open. The outcome is uncertain. If you depend on compounded GLP-1 access, the time to have a backup plan conversation with your prescriber is before this becomes a final rule — not after.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Federal Register notice 2026-08552, May 1, 2026. federalregister.gov
• FDA announcement on proposed exclusion. fda.gov